Guest Gilaad G. Kaplan discusses Risankizumab for ulcerative colitis with JAMA Editor. Topics include personalized therapy with monoclonal antibodies targeting IL-23 pathway, phase 3 trial results showing higher remission rates, complexities in comparing risankizumab to placebo, and the importance of precision medicine in treatment strategies.